Archives: Speakers

Mauricio La Fuente Isetta is the Chief Compliance Officer of Bnext (the leading mobile-first neobank of Spain). In this role, Mauricio is responsible for the Entity’s compliance program design and implementation, promoting and ensuring the compliance with laws, regulations and policies, including chairing the AML/CTF and Corporate Crime Prevention Internal Control bodies, as well as supervising compliance with all aspects inherent to e-money and payment services.
For the past eight years he has been working extensively in corporate compliance and AML/CTF related matters acting as the Head of Compliance & MLRO within the financial sector across Europe.
Prior to joining Bnext, Mauricio was appointed as the Global Head of Compliance for BBVA’s Fintech Denizen Financial. Before his time in Denizen Financial, Mauricio held responsibilities as Head of Compliance Europe for Dollar Financial Global Corp and as Senior Regional Compliance Iberia/France/Benelux for MoneyGram International Ltd.
Mauricio earned a J.D. in Law from UPB, a Master’s Degree in Corporate Finance from EAE Business School and a specialty degree on Regulatory Compliance & US Law from Fordham University School of Law.
He was awarded in 2014 with the Rising Star award from MoneyGram, is a Council member of the Gerson Lehrman Group and an active member of the Spanish Compliance Association – ASCOM.
Mauricio La Fuente Isetta
Chief Compliance Officer Bnext
Madrid
Spain

Christian Friis – (Strategic Trial Planning Manager) brings more than 20 years of experience from the industry. Christian has worked in Regulatory, as CRA in a CRO and as International Trial Manager in Biotech for close to eight years. In 2010 Christian joined Ferring where he has had several roles with increasing responsibilities and latest he progressed into the role as Clinical Project Leader, in Global Clinical Operations. In 2021 Christian joined Global Trial Planning at Novo Nordisk and he is responsible for country allocation of the haemophilia trial portfolio.

Pernille Hemmingsen has more than a decade of experience in the development of pharmaceutical products. With a background in biophysical chemistry and chemical engineering, she is particularly interested in the development of robust manufacturing methods and solid quality to enable the best patient experience and convenience. This interest has led to the development of products ranging from cancer targeting liposomes and antibody drug conjugates to tamper resistant tablets and enhanced diabetes formulations at companies including Genmab and Novo Nordisk. Currently, Pernille Hemmingsen is responsible for the chemistry, manufacturing and control at Adcendo, taking to role as CTO. This work particularly includes establishing an efficient supply chain that encompasses elements from both biologics and small molecules. Pernille holds a Ph.D. from the Department of Chemistry at the Technical University of Denmark and an executive Master of Business Administration from Copenhagen Business School.